drugset / Trial / NCT00623103

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

NCT00623103

Phase 3 Completed 583 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated with PD.

Timeline

Start
2008-01
Primary completion
2010-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivastigmine Small molecule 9.5 mg Oral
Subject Rivastigmine Small molecule 12 mg Oral

Indications